Working... Menu

Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03618056
Recruitment Status : Recruiting
First Posted : August 7, 2018
Last Update Posted : February 11, 2019
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : September 15, 2020
  Estimated Study Completion Date : September 15, 2020